Clinical Trial ProgressEYPT made significant progress as the first patient was dosed in the LUGANO Phase III wet AMD trial.
Market PerformanceEYPT shares are up more than 30% following the release of positive interim clinical data from its Phase 2 VERONA trial investigating DURAVYU in diabetic macular edema.
Treatment Efficacy And SafetyDuravyu demonstrated an early and sustained improvement in both BCVA and CST, with no DURAVYU associated ocular serious adverse events reported, highlighting its favorable safety profile.